Biomarkers /
TSLP
Overview
TSLP is altered in 0.34% of all cancers with glioblastoma, adenocarcinoma of the gastroesophageal junction, anal squamous cell carcinoma, basal cell carcinoma, and colorectal adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in TSLP are TSLP G146E (0.09%), TSLP M1? (0.07%), TSLP P3S (0.07%), TSLP R149C (0.09%), and TSLP R150C (0.07%) [3].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.